Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022-Reference-Cited by-同舟云学术

Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022

Published:2024-06-20 Issue:8 Volume:29 Page:1074-1080
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Nozawa Kazuki^ORCID,Ozaki Yukinori,Yoshinami Tetsuhiro,Yokoe Takamichi,Nishio Hiroshi,Tsuchihashi Kenji,Ichihara Eiki,Miura Yuji,Endo Makoto,Yano Shingo,Maruyama Dai,Susumu Nobuyuki,Takekuma Munetaka,Motohashi Takashi,Ito Mamoru,Baba Eishi,Ochi Nobuaki,Kubo Toshio,Uchino Keita,Kimura Takahiro,Kamiyama Yutaro,Nakao Shinji,Tamura Shinobu,Nishimoto Hitomi,Kato Yasuhisa,Sato Atsushi,Takano Toshimi

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02570-8.pdf

Reference15 articles.

1. Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48. https://doi.org/10.3322/CAAC.21763

2. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266. https://doi.org/10.1002/CNCR.21847

3. Eldar-Lissai A, Cosler LE, Culakova E et al (2008) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 11(2):172–179. https://doi.org/10.1111/j.1524-4733.2007.00242.x

4. Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433–2453. https://doi.org/10.1016/j.ejca.2006.05.002

5. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439